Aug 2026· Nature Medicine· 0 citations· 213 references
Medicine
TL;DR
This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological medicines.
This review summarizes the trajectory of iPSC reprogramming technologies and identifies the core “translational triltrilas”, namely, the inherent tradeoffs between security, homogeneity, and scalability, and proposes a comprehensive strategy to overcome these bottlenecks.
Mengmeng Chen, Ning Zuo, Qi Wang et al.· Frontiers in Cell and Develo...· 0 citations
Induced pluripotent stem cells have revolutionized biomedical research—yet the vast majority of life on Earth remains beyond their reach. Non-model species lack the annotated genomes, validated reagents, and species-specific culture infrastructure that make iPSC technology routine in humans and mice, and this infrastructure deficit, compounded by genuine biological differences in pluripotency network architecture across taxa, is what has kept the field narrow. The deep conservation of the core pluripotency network across vertebrates suggests that reprogramming may, in principle, be achievable across a far broader range of species than currently demonstrated—though the extent to which this holds across more divergent taxa remains to be established. This review consolidates current progress and future potential of iPSC technology across five domains: technical reprogramming challenges and advances; conservation applications including genetic rescue, in vitro gametogenesis, and de-extinction; medical applications within a one medicine framework; agricultural applications spanning disease resistance, climate resilience, and cultured meat; and species-specific iPSC-derived systems in ecotoxicology. Throughout, we distinguish what has been demonstrated from what remains aspirational and identify the priorities that will determine whether the iPSC revolution can be extended—rigorously and at scale—beyond model organism research.
Qiuye Bao, Nicole Liling Tay, Christina Yingyan Lim et al.· Cells· 0 citations
Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.
Ivan Tesakov, M. Nasri, M. Klimiankou et al.· Frontiers in Immunology· 0 citations
The article traces the trend of directed differentiation technologies evolving from two-dimensional culture to three-dimensional organoids and details their practical applications in diseases such as stroke, Alzheimer's disease, and spinal cord injury—particularly in spinal cord injury models, where transplanted cells have achieved long-distance axonal regeneration and circuit reconstruction.
Dai-Yi Yang· International Journal of Bio...· 0 citations
A standardizable, automatable and time- efficient process for the derivation of monoclonal iPSC lines straight from skin including a comprehensive and cascaded ǪC strategy is developed, moving the field of autologous iPSC manufacturing one step further towards cost-efficient clinical implementation.
D. Haberhausen, Christian Wöhle, Constanze Raab et al.· bioRxiv· 0 citations
Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
R. Joseph, Yu Wang, L. Zhong et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
